Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Splenic aminopeptide oral solution for allergic rhinitis
ChiCTR1900025120Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in allergic rhinitis (AR) comparing Splenic aminopeptide oral solution, Loratadine and Splenic aminopeptide oral solution + loratadine (3 arms). Primary endpoints: Serum specific IgE assay, Blood routine examination and 3 more. Started Aug 2019; status: recruiting.
02
Drugs
spleen polypeptideloratadine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR1900025120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025120.